In light of the COVID-19 pandemic, this platform is a necessity for laboratories and public health organizations as they continue to track the spread and evolution of the virus.
SAN CARLOS, Calif. (PRWEB) January 07, 2021
The U.S. is averaging more than two million COVID-19 tests per day- and has reached over 270,000 daily positives. In an effort to help clinicians and researchers more easily test and track pathogens, like SARS-CoV-2 - Clear Labs, provider of the only fully-automated next-generation sequencing platform for turnkey diagnostics, is announcing a broader partnership with Integrated DNA Technologies (IDT), which develops and manufactures nucleic acid products that support the life sciences industry. Clear Labs’ EUA approved, turnkey sequencing platform for diagnostic screening and genomic surveillance of SARS-CoV-2 utilizes IDT primers as part of its solution.
Based on the success of an existing collaboration between Clear Labs and IDT that focuses on providing food producers with information rich and high-accuracy food safety testing using IDT's oligo products, the new engagement addresses the clinical market during a time when increased clarity into pathogens is more important than ever before.
“This is a significant step forward for the clinical market, as we broaden availability for the first fully-integrated and fully-automated NGS platform for clinical diagnostics,” said Jeff Field, Chief Commercial Officer at Clear Labs. “With the support of IDT and it’s targeted sequencing capabilities, we are delivering a reliable and accurate solution that leans on the power of genomics to provide more accurate answers into novel pathogens. In light of the COVID-19 pandemic, this platform is a necessity for laboratories and public health organizations as they continue to track the spread and evolution of the virus.”
IDT serves more than 130,000 life sciences researchers with more than 98,000 nucleic acids produced daily. By integrating with Clear Labs’ platform that combines DNA sequencing, robotics and cloud-based analytics, the companies are delivering more in-depth insights into pathogens, while revealing deeper genomic characterization such as subtyping, antimicrobial resistance, tracking infection clusters, and real-time contact tracing. The Clear Labs approach is also cost-effective, leveling the playing field so that more researchers, clinicians, and laboratorians can tap into genomics for better testing and ultimately, better outcomes.
“Our existing partnership with Clear Labs is proof of the power of our collective efforts to deliver better analysis into complex issues,” said Roman Terrill, Senior Vice President of IDT. “With NGS, robotic automation, and oligos, our approach will facilitate breakthroughs that can better support the clinical market.”
The Clear Labs EUA-approved, turnkey sequencing platform for diagnostic screening and genomic surveillance of SARS-CoV-2, is available now. For more information, visit https://www.clearlabs.com/covid-19/.
About Clear Labs
Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for clinical and applied markets. By creating the only fully-automated platform that brings together DNA sequencing, robotics and cloud-based analytics, Clear Labs democratizes genomics applications to deliver increased clarity. Clear Labs’ turnkey platform accelerates outcomes and improves accuracy - from food-borne pathogens to infectious diseases, including SARS CoV-2. With a novel approach, Clear Labs is helping the world better understand, track and mitigate tomorrow’s novel pathogens. For more information, visit https://www.clearlabs.com/.
Integrated DNA Technologies, Inc. (IDT) develops, manufactures, and markets nucleic acid products for the life sciences industry in the areas of academic and commercial research, agriculture, medical diagnostics, and pharmaceutical development. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Through its GMP services, IDT manufactures products used in diagnostic tests for many forms of cancer and most inherited and infectious diseases. IDT is widely recognized as the industry leader in custom nucleic acid manufacture, serving over 120,000 life sciences researchers. IDT has its manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Leuven, Belgium; and Singapore.